Dendritic cell vaccine modified by murine mAFP gene enhances immunoprotective effect on liver carcinogenesis and tumor development in mice.
- Author:
Yu-An XIE
1
;
Zhi-Peng KUANG
;
An-Min LIANG
;
Xiao-Ling LUO
;
Fan YANG
;
Ji-Ning WU
Author Information
- Publication Type:Journal Article
- MeSH: Adenoviridae; genetics; Animals; B7-1 Antigen; metabolism; Cancer Vaccines; Carbon Tetrachloride; Cells, Cultured; Dendritic Cells; cytology; immunology; metabolism; Diethylnitrosamine; Ethanol; Genetic Vectors; Histocompatibility Antigens Class I; metabolism; Histocompatibility Antigens Class II; metabolism; Intercellular Adhesion Molecule-1; metabolism; Liver Neoplasms, Experimental; chemically induced; immunology; prevention & control; Male; Mice; Mice, Inbred C57BL; Random Allocation; Recombinant Proteins; genetics; metabolism; Transfection; alpha-Fetoproteins; genetics; metabolism
- From: Chinese Journal of Oncology 2008;30(4):250-254
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo construct a dendritic cell vaccine transduced by murine alpha-fetoprotein (mAFP) gene, and evaluate its immunoprotective effect on C57BL/6J mice during the induction of hepatocellular carcinoma by diethylnitrosamines, carbon tetrachloride and ethanol.
METHODSDendritic cells (DCs) were induced and augmented by murine IL-4 and GM-CSF, and transfected by recombinant adenovirus engineered with mAFP gene. Major MHC class I and II, B7.1 (CD80), B7.2 (CD86), CD18a, and CD54 molecules on DC were analyzed by FACS. 80 C57BL/6J male mice were randomly divided into 4 groups (20 mice per group): Simple DC inoculated group, pAdBM5-mAFP-DC inoculated group, pAdBM5-mAFP plasmid inoculated group, and PBS control group. They were immunized once with 5 x 10(5) DCs (0.1 ml)/mouse administered s. c. in the left flank or 100 mg pAdBMS-mAFP plasmid/mouse administered i. m. in the left tibialis anterior muscle. Inoculation was conducted once a week for 4 weeks after 3 times consecutive immunization initially. At the same time of immunization, DEN/CCl4/ethanol were given to induce hepatocellular carcinoma. Tumor incidence was assessed after 20 weeks.
RESULTSA transgenic DC vaccine was successfully constructed and the mAFP transgenic DCs expressed high level molecules of major MHC class I and II , B7.1, B7.2, CD18a, and CD54. After the 20-week induction, the incidence of primary hepatocellular carcinoma (PLC) was 70.0% in simple DC inoculated group, 25.0% in pAdBMS-mAFP-DC inoculated group, 65.0% in pAdBM5-mAFP plasmid inoculated group, and 75.0% in PBS control group. There was a significant difference between group B and other groups (P < 0.05).
CONCLUSIONmAFP transgenic DC tumor vaccine inoculation may induce strong immunoprotection against liver carcinogenesis and tumor development and reduce PLC incidence induced by DEN/CCl4/ethanol.